Tachycardia Market size was estimated at over USD 1.5 billion in 2024 and is poised to reach USD 4.8 billion by the end of 2037, expanding at a CAGR of 10.3% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of the tachycardia is estimated at USD 1.6 billion.
The enlarging population of cardiovascular disease (CVD) and coronary heart disease (CHD) patients around the world is a major growth driver in the tachycardia market. According to a study report, published by NLM in July 2023, around 300,000 mortality cases are registered in the U.S. each year due to ventricular tachycardia (VT) and ventricular fibrillation. The results further revealed that approximately 50% of the total cardiac fatalities are caused by ventricular tachyarrhythmias, where VT was identified among 15% of the CHD patients. The rising prevalence of these heart-related disorders has dragged the focus of the healthcare industry to expand its territory in this sector.
Further, the significant impact on normal lifestyle and growing mortality cases are boosting the demand for proven solutions in the tachycardia market. With the developments in the cardiovascular treatment industry, more categorized solutions are being introduced such as catheter ablation to address specific conditions. Associated methods and tools are now increasingly being preferred by many healthcare professionals. For instance, the industry size of cardiac ablation is projected to reach USD 20.0 billion by the end of 2037, augmenting a notable CAGR of 13.4%. It is also estimated to be evaluated at USD 4.2 billion in 2025 – according to a Research Nester report.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
10.3% |
|
Base Year Market Size (2024) |
USD 1.5 billion |
|
Forecast Year Market Size (2037) |
USD 4.8 billion |
|
Regional Scope |
|
End user (Hospitals & Clinics, Specialty Centers, Ambulatory Surgical Centers)
In tachycardia market, hospitals & clinics segment is set to capture revenue share of over 47.2% by 2037. This segment is pledged by the increasing rate of hospitalization due to the well-equipped infrastructure of these healthcare organizations. The adaptive nature and wide consumer base are some of the major contributors to the growing expenditure in hospitals for CVD care. As per the NLM study, published in January 2022, the inpatient cost constituted 70% of the total CVD hospitalization expenses, where the share of equipment was 50% in India. It further, accounted for the patient cost in treating such heart-related diseases to be USD 3842. Thus, the tendency and frequency of investing in this sector for these multi-specialty hospitals is higher.
Type (Supraventricular Tachycardia, Ventricular Tachycardia, Sinus Tachycardia)
Based on type, the supraventricular tachycardia (SVT) segment is projected to secure a remarkable income for the tachycardia market by the end of 2037. With a high prevalence rate and severity, this type of cardiac condition is experiencing a surge in associated treatments and management therapies. The broadened spectrum of target age groups, from adults to children is also a matter of concern, forcing healthcare service providers to acquire sufficient supplies for early prevention and intervention. For instance, in March 2021, the Arrhythmia Alliance published the Arrhythmia Alliance Healthcare Pioneers Report to attain best practices in caring for SVT. It was also intended to inspire more medical centers to adopt innovative solutions such as atrial fibrillation (AF) and syncope.
Our in-depth analysis of the global tachycardia market includes the following segments:
|
End user |
|
|
Type |
|
|
Treatment |
|
|
Diagnosis |
|
North America Market Analysis
By 2037, North America tachycardia market is expected to capture over 55.3% share. The region consists of a strong cardiac care delivery channel across developed countries such as the U.S. and Canada, empowering its progress in this sector. In addition, the presence of reputed research institutions and pharma companies helps these forefronts bring diversity and improvement in offerings. The speedy allowances for market distribution act as an additional support system for regional development. For instance, in November 2024, a beta-adrenergic blocker, RAPIBLYK (landiolol) for injection was approved in the U.S. to be used in managing supraventricular tachycardia. The injectable indicates the short-term reduction of ventricular rate.
The U.S. is augmenting its domestic tachycardia market with medical advancements and increased healthcare expenditure. In addition, the growing population of high-risk CVD patients is fostering a fruitful trading environment for global leaders, encouraging them to participate in this scenario. For instance, in May 2024, Adagio Medical, Inc. started the FULCRUM-VT Early Feasibility (EFS IDE) study on its recently marketed vCLAS technology. The company shares its plans to utilize the FDA approval, based on the results of this study to expand the product reach of its VT Cryoablation System in this country.
Canada is marking its leading position in the tachycardia market with supportive government initiatives and funding. Its public health authorities are heavily investing in R&D to bring new solutions to offer a complete set of prevention, treatment, and diagnosis across the country, which feedstocks innovation in this sector. For instance, in May 2022, the government of Canada released a grant of USD 5.0 million to leverage the national research capabilities on heart failure. The funding was allocated to 100 researchers from this country to magnify the efforts in improving healthcare services.
APAC Market Statistics
The Asia Pacific tachycardia market is anticipated to garner the fastest growth in the global landscape during the forecast period. The growing economic burden due to a steady rise in CVD prevalence is the major driving factor of this region. According to the NM report, published in July 2024, crude cardiovascular fatality in Asia is predicted to grow by 91.2% between the period, 2025-2050. It further mentioned the volume of CVD death cases to account for 60% of the global amount in 2019. Developing countries including Japan, China, and India are meticulously working on the enhancement of healthcare infrastructure to avail maximum amenities to the patients. Their promotional activities to spread knowledge about early detection and treatment have notably contributed to the enlargement of this sector.
India is one of the emerging leaders in the tachycardia market of this region. The country has shown continuous improvement in delivering better medical services in the last decade. It plans to create a lucrative investment opportunity for both domestic and international companies to emphasize its cardiac care industry. According to the 2023 World Integrated Trade Solutions report, the total value of imported pacemakers in India was registered at USD 53,071.75 thousand. It purchased 87,642 items of the same product from Malaysia, Singapore, Germany, Switzerland, the U.S., Ireland, Mexico, the Dominican Republic, Uruguay, China, Belgium, and the Czech Republic in 2023.
China is a large supplier of the tachycardia market, backed by its excellent manufacturing capabilities and recent developments in healthcare. Despite being a production house of many crucial components and products related to this sector such as pacemakers, it has founded good import-export relationships with foreign forces to ensure a profitable business flow. According to 2022 OEC data, China was marked among the top importers of pacemakers with a value of USD 359.0 million. On the other hand, another 2022 OEC report states, that the export of medical instruments in the country was valued at USD 12 billion, making it the 4th largest exporter in the world.
Key players in the tachycardia market are now focused on extensive clinical trials to establish the effectiveness of their offerings. Considering the growing demand for early prevention, they are also extending their diagnostic portfolio to solidify their position in this sector. For instance, in July 2023, Biosense Webster, Inc. launched OPTRELL Mapping Catheter with TRUEref Technology in the U.S. market. The high-density diagnostic catheter is equipped with the CARTO 3 System, delivering quality visuals in electrophysiological mapping of complex cardiac arrhythmia such as tachycardia. In addition, they are engaging in strategic partnerships and investments for globalization. Such dynamic leaders include:
Author Credits: Radhika Pawar
Copyright © 2025 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?